The Fluc family of proteins comprises small, electrodiffusive fluoride channels, which prevent accumulation of toxic F ions in microorganisms. Recent crystal structures have confirmed their unusual architecture, in which a pair of antiparallel subunits convenes to form a dimer with a twofold symmetry axis parallel to the plane of the membrane. These structures have also revealed the interactions between Fluc channels and several different fibronectin domain monobodies that inhibit Fluc-mediated F currents; in all structures, each channel binds to two monobodies symmetrically, one on either side of the membrane. However, these structures do not reveal the mechanism of monobody inhibition. Moreover, the results appear to diverge from a recent electrophysiological study indicating that monobody binding is negatively cooperative; that is, a bound monobody on one side of a Fluc channel decreases the affinity of an oppositely bound monobody by ∼10-fold. In this study, we reconcile these observations by probing the mechanism of monobody binding and its negative cooperativity using electrophysiological experiments in planar lipid bilayers. Our results indicate that monobody inhibition occurs via a pore-blocking mechanism and that negative cooperativity arises from electrostatic repulsion between the oppositely bound monobodies. A single glutamate residue, on a loop of the monobody that extends into the channel interior, is responsible for negatively cooperative binding. This glutamate side chain also confers voltage dependence and sensitivity to the concentration of trans-F ion to monobody binding. Neutralization by mutation to glutamine abolishes these electrostatic effects. Monobodies that are amenable to cocrystallization with Fluc channels lack an analogous negatively charged side chain and bind independently to opposite sides of the channel. Thus, this work reveals the source of voltage dependence and negative cooperativity of monobody binding to Fluc channels along with the pore-blocking mechanism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379923PMC
http://dx.doi.org/10.1085/jgp.201611747DOI Listing

Publication Analysis

Top Keywords

monobody binding
16
fluc channels
12
negative cooperativity
12
monobody
9
fluoride channels
8
membrane structures
8
mechanism monobody
8
monobody inhibition
8
negatively cooperative
8
bound monobody
8

Similar Publications

Biologically produced protein drugs are generally susceptible to degradation by proteases and often exhibit immunogenicity. To address this issue, mirror-image peptide/protein binders consisting of D-amino acids have been developed so far through the mirror-image phage display technique. Here, we develop a mirror-image protein binder derived from a monobody, one of the promising protein scaffolds, utilizing two notable technologies: chemical protein synthesis and TRAP display, an improved version of mRNA display.

View Article and Find Full Text PDF
Article Synopsis
  • Mirror-image proteins made from D-amino acids are promising for therapy due to their stability and minimal immune reactions.
  • Development involves creating D-target proteins, selecting L-binders via phage display, and synthesizing D-binders that interact with the natural L-targets.
  • The study focuses on D-monobodies with strong binding to the D-SH2 domain of the BCR::ABL1 kinase, showing potential for therapeutic applications by inhibiting its activity and functioning well in biological settings.
View Article and Find Full Text PDF

Transmembrane receptors that endow mammalian cells with the ability to sense and respond to biomaterial-bound ligands will prove instrumental in bridging the fields of synthetic biology and biomaterials. Materials formed with thiol-norbornene chemistry are amenable to thiol-peptide patterning, and this study reports the rational design of synthetic receptors that reversibly activate cellular responses based on peptide-ligand recognition. This transmembrane receptor platform, termed Extracellular Peptide-ligand Dimerization Actuator (EPDA), consists of stimulatory or inhibitory receptor pairs that come together upon extracellular peptide dimer binding with corresponding monobody receptors.

View Article and Find Full Text PDF

Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.

Cell Commun Signal

October 2024

Institute of Physiological Chemistry, Faculty of Medicine, Philipps-University of Marburg, Karl-Von-Frisch-Straße 2, 35043, Marburg, Germany.

Background: The inability of biologics to pass the plasma membrane prevents their development as therapeutics for intracellular targets. To address the lack of methods for cytosolic protein delivery, we used the type III secretion system (T3SS) of Y. enterocolitica, which naturally injects bacterial proteins into eukaryotic host cells, to deliver monobody proteins into cancer cells.

View Article and Find Full Text PDF

Inhibition and degradation of NRAS with a pan-NRAS monobody.

Oncogene

November 2024

Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.

Article Synopsis
  • - The RAS family GTPases are a key group of oncogenes frequently mutated in human cancers, with mutations found in about 20% of tumors, particularly NRAS mutations present in about 25% of melanomas.
  • - Current therapies have targeted KRAS mutations effectively, but there is a significant lack of treatments specifically aimed at NRAS, making it a critical area for developing new cancer therapies.
  • - This study introduces a new monobody that can bind to both forms of NRAS and inhibit its signaling, offering a promising direction for creating selective inhibitors and potential therapeutics for NRAS and BRAF-mutant melanomas.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!